Literature DB >> 11336709

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

W L Martin1, A P West, L Gan, P J Bjorkman.   

Abstract

The neonatal Fc receptor (FcRn) transports immunoglobulin G (IgG) across epithelia, binding IgG in acidic vesicles (pH < or = 6.5) and releasing IgG in the blood at pH 7.4. Well-ordered FcRn/Fc crystals are prevented by the formation of "oligomeric ribbons" of FcRn dimers bridged by Fc homodimers, thus we crystallized a 1:1 complex between rat FcRn and a heterodimeric Fc containing only one FcRn binding site. The 2.8 A complex structure demonstrates that FcRn uses its alpha2 and beta2-microglobulin domains and carbohydrate to interact with the Fc C(gamma)2-C(gamma)3 interface. The structure reveals conformational changes in Fc and three titratable salt bridges that confer pH-dependent binding, and can be used to guide rational design of therapeutic IgGs with longer serum half-lives.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336709     DOI: 10.1016/s1097-2765(01)00230-1

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  148 in total

1.  IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution.

Authors:  T S Ramalingam; Scott A Detmer; W Lance Martin; Pamela J Bjorkman
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 3.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 4.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

5.  X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Authors:  Adam R Mezo; Vandana Sridhar; John Badger; Paul Sakorafas; Vicki Nienaber
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

6.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

7.  Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Ruiwen Zhang
Journal:  J Control Release       Date:  2016-07-06       Impact factor: 9.776

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

9.  The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding.

Authors:  Andrea E Prota; David R Sage; Thilo Stehle; Joyce D Fingeroth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

10.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.